We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04544787
Recruitment Status : Completed
First Posted : September 10, 2020
Results First Posted : October 15, 2021
Last Update Posted : October 15, 2021
Sponsor:
Collaborators:
Bill and Melinda Gates Foundation
Centers for Disease Control and Prevention
PATH
Celerion
Information provided by (Responsible Party):
Pierre Van Damme, Universiteit Antwerpen

Tracking Information
First Submitted Date  ICMJE July 14, 2020
First Posted Date  ICMJE September 10, 2020
Results First Submitted Date  ICMJE September 18, 2021
Results First Posted Date  ICMJE October 15, 2021
Last Update Posted Date October 15, 2021
Actual Study Start Date  ICMJE October 22, 2018
Actual Primary Completion Date January 31, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 18, 2021)
  • Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events [ Time Frame: Up to 42 days after each vaccination ]
    An SAE is any untoward medical occurrence that at any dose met any of the following conditions:
    • Resulted in death;
    • Was life-threatening;
    • Required inpatient hospitalization or prolongation of existing inpatient hospitalization;
    • Resulted in persistent or significant disability/incapacity;
    • Was a congenital anomaly/birth defect;
    • Was medically important.
    A solicited AE is a pre-selected sign or symptom that occurred within 7 days after each dose, whereas unsolicited AEs were collected throughout the study. Solicited AEs included headache, fatigue, myalgia, arthralgia, paresthesia, anesthesia, paralysis, nausea, vomiting, diarrhea, abdominal pain, and fever. A severe AE is an AE that prevented normal everyday activities and which was not classified as an SAE. A related AE is an AE the investigator considered probably or possibly caused by the study vaccine, meaning that there was a reasonable temporal association or the AE was not attributable to other conditions.
  • Seroprotection Rate After a Single Dose of Novel OPV2 in Former OPV Recipients [ Time Frame: Baseline (Day 0 prior to vaccination) and Day 28 ]
    Seroprotection rate was defined as the percentage of participants with anti-type 2-specific poliovirus neutralizing antibody titers ≥ 1:8. Neutralizing antibodies against poliovirus type 2 were determined using the World Health Organization (WHO) standard microneutralization assay (WHO EPI GEN 93.9). The lower limit of quantitation (LLOQ) was 5.7 and the upper limit of quantitation (ULOQ) was 1448.
Original Primary Outcome Measures  ICMJE
 (submitted: September 7, 2020)
  • Safety: Incidence, type and causality of SAEs and severe AEs [ Time Frame: throughout the study period (199 days) ]
  • Immunogenicity Groups 1 & 2 combined [ Time Frame: Day 28 post first vaccination ]
    seroprotection rate (type 2 specific antibody titers >=1:8) of type 2 polio antibodies, following a single dose of nOPV2 candidate 1
  • Immunogenicity Groups 3 & 4 combined [ Time Frame: Day 28 post first vaccination ]
    seroprotection rate (type 2 specific antibody titers >=1:8) of type 2 polio antibodies, following a single dose of nOPV2 candidate 2
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 18, 2021)
  • Number of Former OPV Recipients With Solicited Adverse Events Within 7 Days of Vaccination With Novel OPV2 [ Time Frame: Up to 7 days after each dose (Day 0-7 post-dose 1 and Day 28-35 post-dose 2) ]
    Participants were asked to complete 7-day diary cards soliciting systemic adverse events and daily oral temperature. Solicited events comprised selected signs and symptoms including headache, fatigue, myalgia, arthralgia, paresthesia, anesthesia, paralysis, nausea, vomiting, diarrhea and abdominal pain, or fever defined as a temperature of 37.5°C or higher. AEs were graded as mild (easily tolerated with minimal discomfort or temperature 37.5°C to 38.0°C), moderate (sufficiently discomforting to interfere with normal everyday activities, or temperature 38.1°C to 39.0°C), or severe (preventing normal everyday activities, or temperatures higher than 39.0°C). AEs were assessed by the investigator for causality. Probably related suggests that a reasonable temporal sequence of the AE with vaccine administration exists and, in the Investigator's clinical judgment, it is likely that a causal relationship exists between the vaccine administration and the AE,
  • Number of Former IPV Recipients With Solicited Adverse Events After Vaccination With Novel OPV2 [ Time Frame: 7 days post-dose (Day 0-7 post-dose 1 and and Day 28-35 post-dose 2) ]
    Participants were asked to complete 7-day diary cards soliciting systemic adverse events and daily oral temperature. Solicited events comprised selected signs and symptoms including headache, fatigue, myalgia, arthralgia, paresthesia, anesthesia, paralysis, nausea, vomiting, diarrhea and abdominal pain, or fever defined as a temperature of 37.5°C or higher. AEs were graded as mild (easily tolerated with minimal discomfort or temperature 37.5°C to 38.0°C), moderate (sufficiently discomforting to interfere with normal everyday activities, or temperature 38.1°C to 39.0°C), or severe (preventing normal everyday activities, or temperatures higher than 39.0°C). AEs were assessed by the investigator for causality. Probably related suggests that a reasonable temporal sequence of the AE with vaccine administration exists and, in the Investigator's clinical judgment, it is likely that a causal relationship exists between the vaccine administration and the AE,
  • Number of Participants With Unsolicited Adverse Events [ Time Frame: Up to 42 days after each vaccination ]
    Unsolicited events comprised other signs and symptoms that participants reported through the end of the study. Each unsolicited AE was rated on a 3-point scale of increasing intensity:
    • Grade 1: Mild; an AE that was easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.
    • Grade 2: Moderate; an AE that was sufficiently discomforting to interfere with normal everyday activities.
    • Grade 3: Severe; an AE that prevented normal everyday activities. Each adverse event was assessed by the investigator for causality as unrelated, unlikely, possibly, or probably related to the vaccination.
  • Number of Former OPV Recipients With Clinically Relevant Laboratory Abnormalities Up to 28 Days After Each Vaccination [ Time Frame: Day 0, Day 7, Day 14, and Day 28 for Groups 1-4 and at Day 35, Day 42, and Day 56 for participants in Groups 2 and 4 ]
    Laboratory assessments were collected at one-week intervals from Day 0 to Day 28 (except for Day 21) and at Days 35, 42, and 56 for participants in Groups 2 and 4 who received a 2nd dose. The Investigator reviewed laboratory values outside the normal range and assessed their clinical relevance. Any clinically relevant abnormal lab values that occurred at any visit up to 28 days after the first vaccination (in combined Groups 1 and 2 and Groups 3 and 4) and up to 28 days (Day 56) after the second dose (Groups 2 and 4) are reported.
  • Number of Former IPV Recipients With Clinically Relevant Laboratory Abnormalities Up to 28 Days After Each Vaccination [ Time Frame: Day 0, Day 7, Day 14, Day 28, Day 35, Day 42 and Day 56 ]
    Laboratory assessments were collected at one-week intervals from Day 0 to Day 56, except for Days 21 and 49. The Investigator reviewed laboratory values outside the normal range and assessed their clinical relevance. Any clinically relevant abnormal laboratory abnormalities that occurred at any visit up to 56 days are reported.
  • Anti-Poliovirus Type-2 Neutralizing Antibody Titers After A Single Dose of Novel OPV2 [ Time Frame: Day 0 and Day 28 ]
    Neutralizing antibodies against poliovirus type 2 were determined using the World Health Organization (WHO) standard microneutralization assay (WHO EPI GEN 93.9). The lower limit of quantitation (LLOQ) was 5.7 and the upper limit of quantitation (ULOQ) was 1448. Data were calculated on log2-transformed type 2 neutralizing titers and back transformed for the presentation below. Values shown as 1448 should be interpreted as ≥ 1448.
  • Seroprotection Rate 28 Days After Two Doses of Novel OPV2 in Former OPV Recipients [ Time Frame: Day 56 ]
    Seroprotection rate was defined as the percentage of participants with anti-type 2-specific poliovirus neutralizing antibodies titers ≥ 1:8.
  • Seroprotection Rate in Former IPV Recipients [ Time Frame: Day 0, Day 28, and Day 56 ]
    Seroprotection rate was defined as the percentage of participants with anti-type 2-specific poliovirus neutralizing antibodies titers ≥ 1:8.
  • Seroconversion Rate After a Single Dose of Novel OPV2 in Former OPV Recipients [ Time Frame: Day 28 ]
    Seroconversion is defined as a change from seronegative to seropositive (poliovirus type-2-specific neutralizing antibody titers ≥ 1:8), or for participants seropositive at Baseline, an antibody titer increase of ≥ 4-fold over Baseline titer.
  • Seroconversion Rate After Two Doses of Novel OPV2 in Former OPV Recipients [ Time Frame: Day 56 ]
    Seroconversion is defined as a change from seronegative to seropositive (poliovirus type-2-specific neutralizing antibody titers ≥ 1:8), or for participants seropositive at Baseline, an antibody titer increase of ≥ 4-fold over Baseline titer.
  • Seroconversion Rate in Former IPV Recipients [ Time Frame: Day 28 and Day 56 ]
    Seroconversion is defined as a change from seronegative to seropositive (poliovirus type-2-specific neutralizing antibody titers ≥ 1:8), or for participants seropositive at Baseline, a poliovirus type-2-specific neutralizing antibody titer increase of ≥ 4-fold over Baseline titer.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 7, 2020)
  • Safety: Incidence, type, causality and severity of solicited AEs Groups 1 & 2 [ Time Frame: Days 0-7 in Groups 1 and 2 combined and days 28-35 in Group 2 ]
  • Safety: Incidence, type, causality and severity of solicited AEs Groups 3 & 4 [ Time Frame: Days 0-7 in Groups 3 and 4 combined and days 28-35 in Group 4 ]
  • Safety: Incidence, type, causality and severity of solicited AEs Groups 5-7 [ Time Frame: Days 0-7 and Days 28-35 ]
  • Safety: Incidence, type, causality and severity of unsolicited AEs in all groups [ Time Frame: Throughout the study period (199 days) ]
  • Safety: Incidence, causality and description of deviations from normal safety labs Groups 1-4 [ Time Frame: Day 0 , Day 7 , Day 14 and Day 28 for Groups 1-4 and at Day 35, Day 42 and Day 56 for Groups 2 and 4 ]
  • Safety: Incidence, causality and description of deviations from normal safety labs Groups 5-7 [ Time Frame: Day 0, Day 7, Day 14, Day 28, Day 35, Day 42 and Day 56 ]
  • Immunogenecity Groups 1 & 2 combined [ Time Frame: Day 28 ]
    Median titers of type 2 polio antibodies Groups 1 & 2 combined
  • Immunogenecity Groups 3 & 4 combined [ Time Frame: Day 28 ]
    Median titers of type 2 polio antibodies Groups 3 & 4 combined
  • Immunogenecity Groups 5, 6 & 7 [ Time Frame: Day 28 ]
    Median titers of type 2 polio antibodies Groups 5-7
  • Seroprotection rate of type 2 polio antibodies Groups 2 and 4 [ Time Frame: Day 56 ]
  • Median titers of type 2 polio antibodies Groups 2 and 4 [ Time Frame: Day 56 ]
  • Seroprotection rate of type 2 polio antibodies Groups 5-7 [ Time Frame: Day 28 and at Day 56 ]
  • Seroconversion rate of type 2 polio antibodies Groups 1 & 2 [ Time Frame: Day 28 for Groups 1 and 2 combined and at Day 56 in Group 2 ]
  • Seroconversion rate of type 2 polio antibodies Groups 3 & 4 [ Time Frame: Day 28 for Groups 3 and 4 combined and at Day 56 in Group 4 ]
  • Seroconversion rate of type 2 polio antibodies Groups 5-7 [ Time Frame: Day 28 and at Day 56 for Groups 5A, 5B, 6A, 6B and 7A, 7B ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
Official Title  ICMJE A Phase 2, Partial Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines Candidates, in Healthy Adults Previously Vaccinated With Oral Polio Vaccine (OPV) or Inactivated Polio Vaccine (IPV), Compared With Historical Controls Given Sabin OPV2 or Placebo
Brief Summary This study is designed to evaluate the safety and immunogenicity of two novel type 2 oral poliovirus vaccine (nOPV2) candidates (nOPV2 candidate 1 and nOPV2 candidate 2) in adults. The primary objectives of the study include the general safety and immunogenicity of the two candidate vaccines in healthy volunteers previously vaccinated with Sabin monovalent OPV or inactivated polio vaccine (IPV) only.
Detailed Description

Two nOPV2 vaccine candidates have been developed as attenuated serotype 2 polioviruses derived from a modified Sabin 2 infectious complementary deoxyribonucleic acid (cDNA) clone. nOPV2 Candidate 1 (S2/cre5/S15domV/rec1/hifi3) and nOPV2 Candidate 2 (S2/S15domV/CpG40) were generated by modifying the Sabin-2 ribonucleic acid (RNA) sequence to improve phenotypic stability and make the strains less prone to reversion to virulence. The novel vaccine will eventually be licensed based on 3 criteria: a similar safety profile to the currently licensed monovalent OPV2 (mOPV2) of the Sabin strain, non-inferior immunogenicity, and reduced reversion to virulence.

Due to the withdrawal of Sabin monovalent oral polio vaccine type 2 and prohibition of its use from April 2016 onward, well before the availability of nOPV2 for clinical testing, a head to head comparison of nOPV2 and mOPV2 is not possible. For these reasons, Phase 4 trials have been conducted with Sabin mOPV2 to provide control data on safety, immunogenicity, against which data for nOPV2 in subsequent Phase I and II studies will be evaluated and compared. The Phase 4 trials of Sabin mOPV2 were designed to parallel the expected design of the Phase 1 and 2 nOPV2 studies with respect to overall design, inclusion of similar study cohorts.

This study is designed to evaluate the safety and immunogenicity of two novel type 2 OPV candidates in adults before testing in young children and then infants. The study will include both OPV-vaccinated and IPV-vaccinated adults to provide safety and immunogenicity data relevant to the decision to advance to future studies with testing in children who have not been exposed to OPV2. The primary objectives of the study include the general safety and immunogenicity of the two candidate vaccines, primarily based on comparison with historical data obtained in a Phase 4 study of Sabin mOPV2 for OPV-vaccinated subjects, in order to establish non-inferior immunogenicity and acceptable safety profile. Assessment of the general safety of the 2 candidate vaccines in IPV-only vaccinated participants will be based on comparison with data from a placebo group.

The phase 4 control study (UAM1) used for the comparison in this study is registered with EudraCT (2015-003325-33). Participants were healthy adults aged 18-50 years with documented history of at least three polio vaccinations, including OPV, and were randomly assigned to either one dose or two doses of monovalent OPV2. Between January and March 2016, 100 volunteers were enrolled and randomly assigned to receive one or two doses of monovalent OPV2 (n=50 in each group).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

In this partial-blind study participants will be randomized into one of the following groups:

OPV-vaccinated adults:

  • 1 dose of nOPV2 candidate 1 (Group 1);
  • 2 doses of nOPV2 candidate 1 (Group 2);
  • 1 dose of nOPV2 candidate 2 (Group 3);
  • 2 doses of nOPV2 candidate 2 (Group 4);

IPV-only vaccinated adults:

  • 2 doses of nOPV2 candidate 1 (Group 5);
  • 2 doses of nOPV2 candidate 2 (Group 6);
  • 2 doses of placebo (Group 7).

The first 100 OPV-vaccinated participants will be randomly assigned 1:1 to Groups 3 (1 dose) and 4 (2 doses) to receive nOPV2-c2. The second 100 OPV-vaccinated participants will be randomly assigned 1:1 to Groups 1 (1 dose) and 2 (2 doses) to receive nOPV2-c1. IPV-vaccinated adults will be enrolled in parallel and randomly assigned 2:1 to Group 6 (2 doses of nOPV2-c2) or Group 7 (2 doses of placebo), until Group 6 enrollment is complete, when 2:1 randomization will be continued for Group 5 (2 doses of nOPV2-c1) and Group 7 (2 doses of placebo).

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

All OPV-vaccinated participants will receive one of the nOPV2 candidates candidates in a single blind manner and all IPV- vaccinated participants will receive one of the nOPV2 candidates or placebo in a double-blinded manner.

For the study duration participants and blinded study staff responsible for safety evaluation of IPV participants will not have any information of what has been administered. As the placebo can be distinguished from the vaccine candidates in packaging and color, reception of the vaccines, dose preparation and administration will be done by a team of unblinded study personnel. Appropriate measures will be taken at the site to ensure blinding of subjects and blinded team for the duration of the study.

Primary Purpose: Prevention
Condition  ICMJE Poliomyelitis
Intervention  ICMJE
  • Biological: Novel OPV2 candidate 1

    Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).

    Modifications included the following:

    • Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.
    • Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events
    • Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination.
  • Biological: Novel OPV2 candidate 2

    Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).

    Modifications included the following:

    • Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.
    • silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission.
  • Biological: Placebo
    sugar syrup, propylene glycol (Sirupus simplex, Propylenglycolum, European Pharmacopoeia)
Study Arms  ICMJE
  • Experimental: Group 1: One Dose of Novel OPV2 Candidate 1
    Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
    Intervention: Biological: Novel OPV2 candidate 1
  • Experimental: Group 2: Two Doses of Novel OPV2 Candidate 1
    Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
    Intervention: Biological: Novel OPV2 candidate 1
  • Experimental: Group 3: One Dose of Novel OPV2 Candidate 2
    Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
    Intervention: Biological: Novel OPV2 candidate 2
  • Experimental: Group 4: Two Doses of Novel OPV2 Candidate 2
    Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
    Intervention: Biological: Novel OPV2 candidate 2
  • Experimental: Group 5: Two Doses of Novel OPV2 Candidate 1
    Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
    Intervention: Biological: Novel OPV2 candidate 1
  • Experimental: Group 6: Two Doses of Novel OPV2 Candidate 2
    Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
    Intervention: Biological: Novel OPV2 candidate 2
  • Placebo Comparator: Group 7: Two Doses of Placebo
    Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).
    Intervention: Biological: Placebo
Publications * De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, Modlin J, Clemens R, Costa Clemens SA, Bachtiar NS, Van Damme P. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021 Jan 2;397(10268):39-50. doi: 10.1016/S0140-6736(20)32541-1. Epub 2020 Dec 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 7, 2020)
250
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 8, 2019
Actual Primary Completion Date January 31, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. For Groups 1, 2, 3 and 4: healthy males or females, from 18 to 50 years of age inclusive, having previously received at least 3 doses of OPV more than 12 months before the start of the study;
  2. For Groups 5, 6 and 7: healthy males or females, from 18 to 50 years of age inclusive, having previously received at least 3 doses of IPV more than 12 months before the start of the study;
  3. Having residence in Belgium;
  4. In good physical and mental health as determined on the basis of medical history and general physical examination performed at Day 0;
  5. Female subjects of childbearing potential must agree to the use of an effective method of birth control throughout the study and up to 3 months after last vaccine dose;
  6. Willing to adhere to the prohibitions and restrictions specified in this protocol;
  7. Informed Consent Form (ICF) and Code of Conduct signed voluntarily by the subject before any study-related procedure is performed, indicating that the subject understands the purpose of any procedures required for the study and is willing to participate in the study.

Exclusion Criteria:

  1. A condition that, in the opinion of the Investigator, could compromise the well-being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements;
  2. For Groups 5, 6 and 7: ever having received any OPV in the past;
  3. Any travel to polio endemic countries or countries with evidence of recent (within last 6 months) wild or vaccine-derived poliovirus circulation during the total duration of the study;
  4. Professional handling of food, catering or food production activities during the total duration of the study;
  5. Having Crohn's disease or ulcerative colitis or having had major surgery of the gastrointestinal tract involving significant loss or resection of the bowel;
  6. A known allergy, hypersensitivity, or intolerance to the study vaccine or the placebo, or to any of their components or to any antibiotics;
  7. Any confirmed or suspected immunosuppressive or immunodeficiency condition (including human immunodeficiency virus [HIV] infection, hepatitis B or C infections or total serum immunoglobulin A [IgA] level below laboratory lower limit of normal [LLN]);
  8. Will have household or professional contact with known immunosuppressed people or people without full polio vaccination (i.e. complete primary infant immunization series), e.g. babysitting during the total duration of the study;
  9. Neonatal nurses or others having professional contact with children under 6 months of age during the total duration of the study;
  10. Chronic administration (i.e., longer than 14 days) of immunosuppressant drugs or other immune-modifying drugs within 6 months prior to the first vaccine dose or planned use during the study. For instance, for corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day (inhaled and topical steroids are allowed whereas intra-articular and epidural injection/administration of steroids are not allowed);
  11. Presence of contraindications to administration of the study vaccine on Day 0: acute severe febrile illness deemed by the Investigator to be a contraindication for vaccination or persistent diarrhea or vomiting;
  12. Indications of drug abuse or excessive use of alcohol at Day 0 (males: > 21 units/week; females > 14 units/week);
  13. Being pregnant or breastfeeding. Women of childbearing potential will undergo a urine pregnancy test at each vaccination visit. Subjects with a positive pregnancy test will be excluded;
  14. Participation in another clinical study within 28 days prior to entry in this study or receipt of any investigational product (drug or vaccine) other than the study vaccine within 28 days prior to the first administration of study vaccine, or planned use during the study period;
  15. Administration of any vaccine other than the study vaccine within 28 days prior to the first dose of study vaccine and during the entire study period;
  16. Administration of any polio vaccine within 12 months before the start of the study;
  17. Having had a transfusion of any blood product or application of immunoglobulins within the 4 weeks prior to the first administration of study vaccine or during the study;
  18. Subject is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, or is a family member of an employee or the Investigator, or was a study subject in the historical control studies UAM1 or UAT1 or in the study UAM4a (NCT03430349);
  19. Having a family or household member participating in the study CVIA 065 (NCT04232943) or being a study subject in the study CVIA 065.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04544787
Other Study ID Numbers  ICMJE UAM4
2018-001684-22 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Pierre Van Damme, Universiteit Antwerpen
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Pierre Van Damme
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Bill and Melinda Gates Foundation
  • Centers for Disease Control and Prevention
  • PATH
  • Celerion
Investigators  ICMJE
Principal Investigator: Pierre Van Damme, Prof. MD Centre for the evaluation of vaccination
PRS Account Universiteit Antwerpen
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP